Mural Oncology plc - Ordinary Shares (MURA)
2.6100
+0.0200 (0.77%)
NASDAQ · Last Trade: May 9th, 3:22 PM EDT
The company will cut approximately 90% of its workforce as part of the strategic shift.
Via Stocktwits · April 15, 2025
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via Chartmill · April 15, 2025
Curious about the most active stocks on Tuesday? Find out which stocks are dominating the market action!
Via Chartmill · April 15, 2025
Shares of Mural Oncology plc (NASDAQ: MURA) are soaring Monday following the company's announcement that it will discontinue clinical development of its lead drug candidate Nemvaleukin and begin exploring strategic alternatives.
Via Benzinga · April 15, 2025
Via Benzinga · April 15, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.
Via Chartmill · April 15, 2025
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · April 15, 2025
Via Benzinga · April 15, 2025
Via Benzinga · April 15, 2025
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via Chartmill · March 25, 2025
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Via Chartmill · March 25, 2025
Via Benzinga · March 25, 2025
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill · March 25, 2025
Via Benzinga · March 25, 2025
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · March 25, 2025
Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials for melanoma continue into 2025.
Via Benzinga · March 25, 2025
Via Benzinga · March 25, 2025
Via Benzinga · March 25, 2025

Via Benzinga · January 27, 2025

Via Benzinga · November 25, 2024

Via Benzinga · October 4, 2024

Via Benzinga · October 4, 2024